Roche showcased early-access data from its new Axelios 1 sequencing‑by‑expansion (SBX) nanopore platform at AMP, with comparisons to Illumina NovaSeq that showed high concordance for tumor‑normal pairs and ctDNA mutation detection. Roche also previewed concurrent variant and methylation detection and emphasized the system’s speed and automated library prep for clinical workflows. Hartwig Medical Foundation’s Edwin Cuppen presented >90X tumor and >30X normal data from 60 matched pairs and reported similar genome coverage, SNV/indel detection and variant allele frequencies between Axelios and NovaSeq. Roche highlighted automated batch preps and tools (XOOS) for secondary analysis as enablers of faster turnarounds for oncology research and potential clinical applications. If Axelios maintains data quality at scale, it could challenge existing short‑read incumbents for cancer genomics and ctDNA labs by offering faster runtimes and integrated methylation calls, prompting labs and test developers to evaluate platform performance, throughput economics, and regulatory pathways.